Secreted protein HT5GJ57

Abstract

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

What is claimed is:  
     
         1 . An isolated protein comprising amino acid residues 26 to 190 of SEQ ID NO:161.  
     
     
         2 . The isolated protein of  claim 1  which comprises amino acid residues 2 to 190 of SEQ ID NO:161.  
     
     
         3 . The isolated protein of  claim 1  which comprises amino acid residues 1 to 190 of SEQ IDNO:161.  
     
     
         4 . The protein of  claim 1  which comprises a heterologous polypeptide sequence.  
     
     
         5 . A composition comprising the protein of  claim 1  and a pharmaceutically acceptable carrier.  
     
     
         6 . An isolated protein produced by the method comprising: 
 (a) expressing the protein of  claim 1  by a cell; and    (b) recovering said protein.    
     
     
         7 . An isolated protein comprising the amino acid sequence of the secreted portion of the polypeptide encoded by the HT5GJ57 cDNA contained in ATCC Deposit No. 209889.  
     
     
         8 . An isolated protein of  claim 7  which comprises the amino acid sequence of the complete polypeptide encoded by the HT5GJ57 cDNA contained in ATCC Deposit No. 209889, excepting the N-terminal methionine.  
     
     
         9 . An isolated protein of  claim 7  which comprises the amino acid sequence of the complete polypeptide encoded by the HT5GJ57 cDNA contained in ATCC Deposit No. 209889.  
     
     
         10 . The protein of  claim 7  which comprises a heterologous polypeptide sequence.  
     
     
         11 . A composition comprising the protein of  claim 7  and a pharmaceutically acceptable carrier.  
     
     
         12 . An isolated protein produced by the method comprising: 
 (a) expressing the protein of  claim 7  by a cell; and    (b) recovering said protein.    
     
     
         13 . An isolated protein comprising a polypeptide sequence which is at least 90% identical to amino acid residues 26 to 190 of SEQ ID NO:161.  
     
     
         14 . The isolated protein of  claim 13  wherein said polypeptide sequence is at least 90% identical to amino acid residues 1 to 190 of SEQ ID NO:161.  
     
     
         15 . The isolated protein of  claim 13  wherein said polypeptide sequence is at least 95% identical to amino acid residues 26 to 190 of SEQ ID NO:161.  
     
     
         16 . The isolated protein of  claim 13  wherein said polypeptide sequence is at least 95% identical to amino acid residues 1 to 190 of SEQ ID NO:161.  
     
     
         17 . The protein of  claim 13  which comprises a heterologous polypeptide sequence.  
     
     
         18 . A composition comprising the protein of  claim 13  and a pharmaceutically acceptable carrier.  
     
     
         19 . An isolated protein produced by the method comprising: 
 (a) expressing the protein of  claim 13  by a cell; and    (b) r ecovering said protein.    
     
     
         20 . An isolated protein comprising a polypeptide sequence which is at least 90% identical to the secreted portion of the polypeptide encoded by the HT5GJ57 cDNA contained in ATCC Deposit No. 209889.  
     
     
         21 . The isolated protein of  claim 20  wherein said polypeptide sequence is at least 90% identical to the complete polypeptide encoded by the HT5GJ57 cDNA contained in ATCC Deposit No. 209889.  
     
     
         22 . The isolated protein of  claim 20  wherein said polypeptide sequence is at least 95% identical to the secreted portion of the polypeptide encoded by the HT5GJ57 cDNA contained in ATCC Deposit No. 209889.  
     
     
         23 . The isolated protein of  claim 20  wherein said polypeptide sequence is at least 95% identical to the complete polypeptide encoded by the HT5GJ57 cDNA contained in ATCC Deposit No. 209889.  
     
     
         24 . The protein of  claim 20  which comprises a heterologous polypeptide sequence.  
     
     
         25 . A composition comprising the protein of  claim 20  and a pharmaceutically acceptable carrier.  
     
     
         26 . An isolated protein produced by the method comprising: 
 (a) expressing the protein of  claim 20  by a cell; and    (b) recovering said protein.    
     
     
         27 . An isolated protein comprising at least 30 contiguous amino acid residues of amino acid residues 26 to 190 of SEQ ID NO:161.  
     
     
         28 . The isolated protein of  claim 27  which comprises at least 50 contiguous amino acid residues of amino acid residues 26 to 190 of SEQ ID NO:161.  
     
     
         29 . The protein of  claim 27  which comprises a heterologous polypeptide sequence.  
     
     
         30 . A composition comprising the protein of  claim 27  and a pharmaceutically acceptable carrier.  
     
     
         31 . An isolated protein produced by the method comprising: 
 (a) expressing the protein of  claim 27  by a cell; and    (b) recovering said protein.    
     
     
         32 . An isolated protein comprising at least 30 contiguous amino acid residues of the secreted portion of the polypeptide encoded by the HT5GJ57 cDNA contained in ATCC Deposit No. 209889.  
     
     
         33 . The isolated protein of  claim 32  which comprises at least 50 contiguous amino acid residues of the secreted portion of the polypeptide encoded by the HT5GJ57 cDNA contained in ATCC Deposit No. 209889.  
     
     
         34 . The protein of  claim 33  which comprises a heterologous polypeptide sequence.  
     
     
         35 . A composition comprising the protein of  claim 33  and a pharmaceutically acceptable carrier.  
     
     
         36 . An isolated protein produced by the method comprising: 
 (a) expressing the protein of  claim 33  by a cell; and    (b) recovering said protein.    
     
     
         37 . An isolated protein comprising at least 30 contiguous amino acid residues of amino acid residues 1 to 190 of SEQ ID NO:161.  
     
     
         38 . The isolated protein of  claim 37  which comprises at least 50 contiguous amino acid residues of amino acid residues 1 to 190 of SEQ ID NO:161.  
     
     
         39 . The protein of  claim 37  which comprises a heterologous polypeptide sequence.  
     
     
         40 . A composition comprising the protein of  claim 37  and a pharmaceutically acceptable carrier.  
     
     
         41 . An isolated protein produced by the method comprising: 
 (a) expressing the protein of  claim 37  by a cell; and    (b) recovering said protein.    
     
     
         42 . An isolated protein comprising at least 30 contiguous amino acid residues of the complete polypeptide encoded by the HT5GJ57 cDNA contained in ATCC Deposit No. 209889.  
     
     
         43 . The isolated protein of  claim 42  which comprises at least 50 contiguous amino acid residues of the complete polypeptide encoded by the HT5GJ57 cDNA contained in ATCC Deposit No. 209889.  
     
     
         44 . The protein of  claim 42  which comprises a heterologous polypeptide sequence.  
     
     
         45 . A composition comprising the protein of  claim 42  and a pharmaceutically acceptable carrier.  
     
     
         46 . An isolated protein produced by the method comprising: 
 (a) expressing the protein of  claim 42  by a cell; and    (b) recovering said protein.